Equities

Irhythm Technologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Irhythm Technologies Inc

Actions
  • Price (EUR)121.00
  • Today's Change0.00 / 0.00%
  • Shares traded25.00
  • 1 Year change+17.48%
  • Beta1.0749
Data delayed at least 15 minutes, as of Feb 11 2026 14:47 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

iRhythm Technologies, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

  • Revenue in USD (TTM)702.57m
  • Net income in USD-51.46m
  • Incorporated2025
  • Employees2.00k
  • Location
    Irhythm Technologies Inc699 8th Street, Suite 600SAN FRANCISCO 94103United StatesUSA
  • Phone+1 (650) 632-5700
  • Fax+1 (302) 655-5049
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.